Literature DB >> 34043615

COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021.

.   

Abstract

COVID-19 vaccines are a critical tool for controlling the ongoing global pandemic. The Food and Drug Administration (FDA) has issued Emergency Use Authorizations for three COVID-19 vaccines for use in the United States.* In large, randomized-controlled trials, each vaccine was found to be safe and efficacious in preventing symptomatic, laboratory-confirmed COVID-19 (1-3). Despite the high level of vaccine efficacy, a small percentage of fully vaccinated persons (i.e. received all recommended doses of an FDA-authorized COVID-19 vaccine) will develop symptomatic or asymptomatic infections with SARS-CoV-2, the virus that causes COVID-19 (2-8).

Entities:  

Year:  2021        PMID: 34043615     DOI: 10.15585/mmwr.mm7021e3

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  116 in total

1.  Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City.

Authors:  Ralf Duerr; Dacia Dimartino; Christian Marier; Paul Zappile; Guiqing Wang; Jennifer Lighter; Brian Elbel; Andrea B Troxel; Adriana Heguy
Journal:  J Clin Invest       Date:  2021-09-15       Impact factor: 14.808

2.  Technical note: The calculated real world BNT162b2 vaccine efficacy was 88% when accounting for asymptomatic cases.

Authors:  Richard Paul Junghans
Journal:  Hum Vaccin Immunother       Date:  2021-12-02       Impact factor: 3.452

3.  Factors associated with decision making on COVID-19 vaccine acceptance among college students in South Carolina.

Authors:  Cheuk Chi Tam; Shan Qiao; Xiaoming Li
Journal:  Psychol Health Med       Date:  2021-09-23       Impact factor: 2.423

4.  Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases.

Authors:  Claire Cook; Naomi J Patel; Kristin M D'Silva; Tiffany Y-T Hsu; Michael DiIorio; Lauren Prisco; Lily W Martin; Kathleen Vanni; Alessandra Zaccardelli; Derrick Todd; Jeffrey A Sparks; Zachary Scott Wallace
Journal:  Ann Rheum Dis       Date:  2021-09-06       Impact factor: 19.103

Review 5.  Diagnostics of messenger ribonucleic acid (mRNA) severe acute respiratory syndrome-corona virus‑2 (SARS-CoV‑2) vaccination-associated myocarditis-A systematic review.

Authors:  Jan M Federspiel; Frank Ramsthaler; Mattias Kettner; Gerhard Mall
Journal:  Rechtsmedizin (Berl)       Date:  2022-07-20       Impact factor: 1.112

6.  Epidemiological and clinical characteristics of SARS-CoV-2 reinfections in a Spanish region.

Authors:  Oriol Yuguero; Maria Companys; Marianela Guzmán; Rita Maciel; Cecília Llobet; Aurora López; Rebeca Olles; Violant Pujol; Maria José Ruiz; Mireia Saura; Carmel Vidal; Pere Godoy
Journal:  SAGE Open Med       Date:  2022-06-27

7.  The impact of COVID-19 vaccination on California's return to normalcy.

Authors:  Maria L Daza-Torres; Yury E García; Alec J Schmidt; Brad H Pollock; James Sharpnack; Miriam Nuño
Journal:  PLoS One       Date:  2022-05-19       Impact factor: 3.752

8.  Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States.

Authors:  Sally B Coburn; Elizabeth Humes; Raynell Lang; Cameron Stewart; Brenna C Hogan; Kelly A Gebo; Sonia Napravnik; Jessie K Edwards; Lindsay E Browne; Lesley S Park; Amy C Justice; Kirsha S Gordon; Michael A Horberg; Julia M Certa; Eric Watson; Celeena R Jefferson; Michael J Silverberg; Jacek Skarbinski; Wendy A Leyden; Carolyn F Williams; Keri N Althoff
Journal:  JAMA Netw Open       Date:  2022-06-01

9.  Examining the impact of COVID-19 vaccination rates on differential access to critical care.

Authors:  Gordon Cromley; Jie Lin
Journal:  Appl Geogr       Date:  2022-06-21

10.  Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples.

Authors:  Timothy A Bates; Hans C Leier; Zoe L Lyski; James R Goodman; Marcel E Curlin; William B Messer; Fikadu G Tafesse
Journal:  JAMA       Date:  2021-07-21       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.